JPH11507964A - 2,5−アンヒドロ−d−マンノース末端構造を持つ、抗原性グループb連鎖球菌▲ii▼型および▲iii▼型多糖断片とその複合ワクチン - Google Patents
2,5−アンヒドロ−d−マンノース末端構造を持つ、抗原性グループb連鎖球菌▲ii▼型および▲iii▼型多糖断片とその複合ワクチンInfo
- Publication number
- JPH11507964A JPH11507964A JP9501648A JP50164897A JPH11507964A JP H11507964 A JPH11507964 A JP H11507964A JP 9501648 A JP9501648 A JP 9501648A JP 50164897 A JP50164897 A JP 50164897A JP H11507964 A JPH11507964 A JP H11507964A
- Authority
- JP
- Japan
- Prior art keywords
- polysaccharide
- gbs
- type
- fragment
- iii
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000004676 glycans Polymers 0.000 title claims abstract description 131
- 150000004804 polysaccharides Polymers 0.000 title claims abstract description 51
- LKAPTZKZHMOIRE-KVTDHHQDSA-N (2s,3s,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolane-2-carbaldehyde Chemical compound OC[C@H]1O[C@H](C=O)[C@@H](O)[C@@H]1O LKAPTZKZHMOIRE-KVTDHHQDSA-N 0.000 title claims description 9
- LKAPTZKZHMOIRE-UHFFFAOYSA-N chitose Natural products OCC1OC(C=O)C(O)C1O LKAPTZKZHMOIRE-UHFFFAOYSA-N 0.000 title claims description 8
- 230000000890 antigenic effect Effects 0.000 title description 6
- 108010060123 Conjugate Vaccines Proteins 0.000 title description 2
- 229940031670 conjugate vaccine Drugs 0.000 title description 2
- 238000000034 method Methods 0.000 claims abstract description 46
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 40
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 40
- 229960005486 vaccine Drugs 0.000 claims abstract description 29
- 241000124008 Mammalia Species 0.000 claims abstract description 7
- 230000003053 immunization Effects 0.000 claims abstract description 6
- 229920001282 polysaccharide Polymers 0.000 claims description 80
- 239000005017 polysaccharide Substances 0.000 claims description 80
- 239000012634 fragment Substances 0.000 claims description 39
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 24
- 210000002966 serum Anatomy 0.000 claims description 19
- 239000003153 chemical reaction reagent Substances 0.000 claims description 18
- LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical group [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 claims description 16
- 229940118376 tetanus toxin Drugs 0.000 claims description 15
- 239000000203 mixture Substances 0.000 claims description 14
- 241000894006 Bacteria Species 0.000 claims description 13
- 108010055044 Tetanus Toxin Proteins 0.000 claims description 11
- 208000015181 infectious disease Diseases 0.000 claims description 9
- 235000010288 sodium nitrite Nutrition 0.000 claims description 8
- 239000007787 solid Substances 0.000 claims description 8
- 239000000427 antigen Substances 0.000 claims description 7
- 108091007433 antigens Proteins 0.000 claims description 7
- 102000036639 antigens Human genes 0.000 claims description 7
- 229910052739 hydrogen Inorganic materials 0.000 claims description 7
- 239000001257 hydrogen Substances 0.000 claims description 7
- 238000003018 immunoassay Methods 0.000 claims description 7
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 claims description 6
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 5
- 101710116435 Outer membrane protein Proteins 0.000 claims description 4
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 claims description 4
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 claims description 4
- 108010071134 CRM197 (non-toxic variant of diphtheria toxin) Proteins 0.000 claims description 3
- 102000028556 IgA binding proteins Human genes 0.000 claims description 3
- 108091009322 IgA binding proteins Proteins 0.000 claims description 3
- 230000001580 bacterial effect Effects 0.000 claims description 3
- 108091008324 binding proteins Proteins 0.000 claims description 3
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 claims description 2
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 claims description 2
- 238000006640 acetylation reaction Methods 0.000 claims description 2
- 229910017604 nitric acid Inorganic materials 0.000 claims description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 claims description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 claims description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 claims description 2
- PZUPAGRIHCRVKN-UHFFFAOYSA-N 5-[5-[3,4-dihydroxy-6-[(3,4,5-trihydroxyoxan-2-yl)oxymethyl]-5-[3,4,5-trihydroxy-6-[(3,4,5-trihydroxyoxan-2-yl)oxymethyl]oxan-2-yl]oxyoxan-2-yl]oxy-3,4-dihydroxy-6-[(3,4,5-trihydroxyoxan-2-yl)oxymethyl]oxan-2-yl]oxy-6-(hydroxymethyl)oxane-2,3,4-triol Chemical group OCC1OC(O)C(O)C(O)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(COC4C(C(O)C(O)CO4)O)O3)O)C(COC3C(C(O)C(O)CO3)O)O2)O)C(COC2C(C(O)C(O)CO2)O)O1 PZUPAGRIHCRVKN-UHFFFAOYSA-N 0.000 claims 4
- 125000000600 disaccharide group Chemical group 0.000 claims 4
- 241000588650 Neisseria meningitidis Species 0.000 claims 3
- 102000016607 Diphtheria Toxin Human genes 0.000 claims 2
- 108010053187 Diphtheria Toxin Proteins 0.000 claims 2
- 102000023732 binding proteins Human genes 0.000 claims 2
- 239000000908 ammonium hydroxide Substances 0.000 claims 1
- 150000007857 hydrazones Chemical class 0.000 claims 1
- 230000021615 conjugation Effects 0.000 abstract description 5
- 238000006243 chemical reaction Methods 0.000 description 19
- 239000013256 coordination polymer Substances 0.000 description 17
- 238000009739 binding Methods 0.000 description 13
- 241000699670 Mus sp. Species 0.000 description 11
- 239000002585 base Substances 0.000 description 9
- 230000004044 response Effects 0.000 description 9
- 241000283973 Oryctolagus cuniculus Species 0.000 description 8
- 125000003172 aldehyde group Chemical group 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 238000005160 1H NMR spectroscopy Methods 0.000 description 5
- 238000002965 ELISA Methods 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 229960000814 tetanus toxoid Drugs 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 4
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 4
- 210000001744 T-lymphocyte Anatomy 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 230000028993 immune response Effects 0.000 description 4
- 230000036039 immunity Effects 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 102000014914 Carrier Proteins Human genes 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 238000003776 cleavage reaction Methods 0.000 description 3
- 239000008367 deionised water Substances 0.000 description 3
- 229910021641 deionized water Inorganic materials 0.000 description 3
- 238000002649 immunization Methods 0.000 description 3
- 230000002163 immunogen Effects 0.000 description 3
- 238000002955 isolation Methods 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 238000007034 nitrosation reaction Methods 0.000 description 3
- 230000001662 opsonic effect Effects 0.000 description 3
- 238000006268 reductive amination reaction Methods 0.000 description 3
- 230000007017 scission Effects 0.000 description 3
- 125000005629 sialic acid group Chemical group 0.000 description 3
- 238000001228 spectrum Methods 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 235000000346 sugar Nutrition 0.000 description 3
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 3
- 229940033663 thimerosal Drugs 0.000 description 3
- 241000486679 Antitype Species 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 108010078791 Carrier Proteins Proteins 0.000 description 2
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
- 201000009906 Meningitis Diseases 0.000 description 2
- 102000003992 Peroxidases Human genes 0.000 description 2
- 241000193990 Streptococcus sp. 'group B' Species 0.000 description 2
- 229960000583 acetic acid Drugs 0.000 description 2
- 238000005903 acid hydrolysis reaction Methods 0.000 description 2
- 150000001299 aldehydes Chemical class 0.000 description 2
- SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 description 2
- 239000002131 composite material Substances 0.000 description 2
- 230000001268 conjugating effect Effects 0.000 description 2
- 230000009615 deamination Effects 0.000 description 2
- 238000006481 deamination reaction Methods 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 150000002016 disaccharides Chemical class 0.000 description 2
- 230000007717 exclusion Effects 0.000 description 2
- 239000012362 glacial acetic acid Substances 0.000 description 2
- MSWZFWKMSRAUBD-IVMDWMLBSA-N glucosamine group Chemical group OC1[C@H](N)[C@@H](O)[C@H](O)[C@H](O1)CO MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 239000002596 immunotoxin Substances 0.000 description 2
- 239000000178 monomer Substances 0.000 description 2
- 230000009935 nitrosation Effects 0.000 description 2
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 2
- 230000000625 opsonophagocytic effect Effects 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 108040007629 peroxidase activity proteins Proteins 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- GHMLBKRAJCXXBS-UHFFFAOYSA-N resorcinol Chemical compound OC1=CC=CC(O)=C1 GHMLBKRAJCXXBS-UHFFFAOYSA-N 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical group OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- SQVRNKJHWKZAKO-OQPLDHBCSA-N sialic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)OC1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-OQPLDHBCSA-N 0.000 description 2
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 2
- 238000000108 ultra-filtration Methods 0.000 description 2
- 238000002255 vaccination Methods 0.000 description 2
- 239000013598 vector Substances 0.000 description 2
- 229920000936 Agarose Polymers 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- 241001569772 Celithemis elisa Species 0.000 description 1
- 241000723347 Cinnamomum Species 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 238000012286 ELISA Assay Methods 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 229920002683 Glycosaminoglycan Polymers 0.000 description 1
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 1
- 241000606768 Haemophilus influenzae Species 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- -1 Lithium cyanoborohydride Chemical compound 0.000 description 1
- UEZVMMHDMIWARA-UHFFFAOYSA-N Metaphosphoric acid Chemical compound OP(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-N 0.000 description 1
- OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 description 1
- OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 description 1
- SQVRNKJHWKZAKO-PFQGKNLYSA-N N-acetyl-beta-neuraminic acid Chemical group CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)O[C@H]1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-PFQGKNLYSA-N 0.000 description 1
- MBLBDJOUHNCFQT-LXGUWJNJSA-N N-acetylglucosamine Natural products CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO MBLBDJOUHNCFQT-LXGUWJNJSA-N 0.000 description 1
- IOVCWXUNBOPUCH-UHFFFAOYSA-M Nitrite anion Chemical compound [O-]N=O IOVCWXUNBOPUCH-UHFFFAOYSA-M 0.000 description 1
- 235000014676 Phragmites communis Nutrition 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- 206010061372 Streptococcal infection Diseases 0.000 description 1
- 241000193985 Streptococcus agalactiae Species 0.000 description 1
- 239000012505 Superdex™ Substances 0.000 description 1
- ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000009824 affinity maturation Effects 0.000 description 1
- 150000008044 alkali metal hydroxides Chemical class 0.000 description 1
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 238000005576 amination reaction Methods 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Natural products N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 1
- 230000005875 antibody response Effects 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 235000017803 cinnamon Nutrition 0.000 description 1
- 229940001442 combination vaccine Drugs 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 230000001143 conditioned effect Effects 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 238000003381 deacetylation reaction Methods 0.000 description 1
- 230000006240 deamidation Effects 0.000 description 1
- 238000012691 depolymerization reaction Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000011026 diafiltration Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 239000012954 diazonium Substances 0.000 description 1
- 150000001989 diazonium salts Chemical class 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000003754 fetus Anatomy 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 125000005640 glucopyranosyl group Chemical group 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229940047650 haemophilus influenzae Drugs 0.000 description 1
- 230000002489 hematologic effect Effects 0.000 description 1
- 150000002373 hemiacetals Chemical class 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 229940124452 immunizing agent Drugs 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000011031 large-scale manufacturing process Methods 0.000 description 1
- 231100000636 lethal dose Toxicity 0.000 description 1
- 125000005647 linker group Chemical group 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 229940031348 multivalent vaccine Drugs 0.000 description 1
- 229950006780 n-acetylglucosamine Drugs 0.000 description 1
- 230000000269 nucleophilic effect Effects 0.000 description 1
- 230000020477 pH reduction Effects 0.000 description 1
- 125000000864 peroxy group Chemical group O(O*)* 0.000 description 1
- 235000020030 perry Nutrition 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 238000003127 radioimmunoassay Methods 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 230000008707 rearrangement Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 102220201851 rs143406017 Human genes 0.000 description 1
- JZWFDVDETGFGFC-UHFFFAOYSA-N salacetamide Chemical group CC(=O)NC(=O)C1=CC=CC=C1O JZWFDVDETGFGFC-UHFFFAOYSA-N 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 125000000467 secondary amino group Chemical class [H]N([*:1])[*:2] 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000012916 structural analysis Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
- A61K39/092—Streptococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/08—Clostridium, e.g. Clostridium tetani
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/085—Staphylococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S424/00—Drug, bio-affecting and body treating compositions
- Y10S424/831—Drug, bio-affecting and body treating compositions involving capsular polysaccharide of bacterium, e.g. polyribosyl ribitol phosphate
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Materials Engineering (AREA)
- Polymers & Plastics (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Virology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1. 次の2,5-アンヒドロ-D-マンノース還元末端構造、を持ち [この式ではR1が水素であり、R2が次の式で表わされるシアリル化された7糖 反復単位からなり、 {この式では、II型についてはnが約5から約50であり、R1が次の式で表わさ れるシアリル化された5糖反復単位であり、 (この式では、III型についてはnが約5から約50であり、R2がαNeuAc(2-3) β-D-Galp1-で表わされる2糖である)}]で表される断片を生産するために、 グループB連鎖球菌II型およびIII型多糖類を脱重合する方法であって、 該方法は、脱重合されるGBS II型またはGBS III型多糖を提供し、水層中の多 糖を塩基と反応させて部分的に脱N-アセチル化された多糖産物を生産し、脱N- アセチル化された多糖産物をニトロソ化試薬で脱重合してGBS II型またはGBS II I型断片を形成し、次いで、この断片を回収する方法。 2. 塩基を水酸化ナトリウム、水酸化カリウム、水酸化アンモニウム、炭酸ナ トリウム、重炭酸ナトリウムおよびヒドラゾンのグループから選ぶ、請求の範囲 第1項にしたがう方法。 3. ニトロソ化試薬が、亜硝酸ナトリウムあるいは硝酸である、請求の範囲第 1項にしたがう方法。 4. 塩基が水酸化ナトリウムであり、ニトロソ化試薬が亜硝酸ナトリウムであ る、請求の範囲第1項にしたがう方法。 5. 多糖がGBS II型細菌から得られる、請求の範囲第4項にしたがう方法。 6. 得られたGBS II型断片が約5kDaから約50kDaの分子量を持つ、請求の範囲 第5項にしたがう方法。 7. 多糖がGBS III型細菌から得られる、請求の範囲第4項にしたがう方法。 8. 得られた断片が約5kDaから約50kDaの分子量を持つ、請求の範囲第7項に したがう方法。 9. 請求の範囲第1項にしたがって調製される、GBS II型またはGBS III型多 糖断片。 10. 脱N-アセチル化するための塩基が水酸化ナトリウムであり、ニトロソ化 試薬が亜硝酸ナトリウムである、請求の範囲第9項にしたがって調製される、GB S II型またはGBS III型多糖断片。 11. 次の2,5-アンヒドロ-D-マンノース還元末端構造を持ち、 [この式ではR1が水素であり、R2が次の式で表わされるシアリル化された7糖 反復単位からなり、 {この式では、II型についてはnが約5から約50であり、R1が次の式で表わさ れるシアリル化された5糖反復単位であり、 (この式では、III型についてはnが約5から約50であり、R2がαNeuAc(2-3) β-D-Galp1-で表わされる2糖である)}]で表されるGBS II型およびIII型多糖 類断片。 12. 分子量が約5kDaから約50kDaの範囲を持つ、請求の範囲第11項にした がうGBS II型多糖断片。 13. 分子量が約5kDaから約50kDaの範囲を持つ、請求の範囲第11項にした がうGBS III型多糖断片。 14. GBS II型およびGBS III型多糖断片から選ばれた、少なくとも一つの多 糖断片からなり、また該断片がタンパク質に共有結合し、複合分子が次の構造式 [この式ではR1が水素であり、R2が次の式で表わされるシアリル化された7糖 反復単位からなり、 {この式では、II型についてはnが約5から約50であり、R1が次の式で表わさ れるシアリル化された5糖反復単位であり、 (この式では、III型についてはnが約5から約50であり、R2がαNeuAc(2-3) β-D-Galp1-で表わされる2糖である)}]で表される複合分子。 15. タンパク質が細菌由来である、請求の範囲第14項にしたがう複合分子 。 16. タンパク質が、破傷風類毒素、ジフテリア毒素、CRM197、Ia/Ib型グル ープB連鎖球菌のβ-C抗原の組み換え型非IgA結合タンパク質、および髄膜炎菌由 来の組み換え型クラス3外膜タンパク質から選ばれた細菌由来である、請求の範 囲第15項にしたがう複合分子。 17. 多糖断片がGBS II型多糖であり、タンパク質が破傷風類毒素であり、多 糖断片の分子量が約5kDaから50kDaである、請求の範囲第16項にしたがう複合 分子。 18. 多糖断片がGBS III型多糖であり、タンパク質が破傷風類毒素であり、 多糖断片の分子量が約5kDaから50kDaである、請求の範囲第16項にしたがう複 合分子。 19. タンパク質に対する多糖のモル比が約1から10である、請求の範囲第 16項にしたがう複合分子。 20. タンパク質に対する多糖のモル比が約3から10である、請求の範囲第 19項にしたがう複合分子。 21. GBS II型およびGBS III型断片からなる、請求の範囲第14項にしたが う複合分子。 22. タンパク質が、Ia/Ib型グループB連鎖球菌のβ-C抗原の組み換え型非Ig A結合タンパク質である、請求の範囲第21項にしたがう複合分子。 23. 複合分子が次の構造式 [この式ではR1が水素であり、R2が次の式で表わされるシアリル化された7糖 反復単位からなり、 {この式では、II型についてはnが約5から約50であり、R1が次の式で表わさ れるシアリル化された5糖反復単位であり、 (この式では、III型についてはnが約5から約50であり、R2がαNeuAc(2-3) β-D-Galp1-で表わされる2糖である)}]で表される、タンパク質に共有結合 したGBS II型およびGBS III型多糖断片からなる、複合分子を含むワクチン組成 物。 24. 断片がGBS II型多糖であり、また多糖断片の分子量が約5kDaから約50kD aである、請求の範囲第23項にしたがうワクチン組成物。 25. 断片がGBS III型多糖であり、また多糖断片の分子量が約5kDaから約50k Daである、請求の範囲第23項にしたがうワクチン組成物。 26. タンパク質が、破傷風類毒素、ジフテリア毒素、CRM197、Ia/Ib型グル ープB連鎖球菌のβ-C抗原の組み換え型非IgA結合タンパク質、および髄膜炎菌由 来の組み換え型クラス3外膜タンパク質から選ばれた細菌由来である、請求の範 囲第23項にしたがうワクチン組成物。 27. タンパク質が、Ia/Ib型グループB連鎖球菌のβ-C抗原の組み換え型非Ig A結合タンパク質、および髄膜炎菌由来の組み換え型クラス3外膜タンパク質で ある、請求の範囲第26項にしたがうワクチン組成物。 28. GBS II型およびGBS III型多糖断片との複合物からなる、請求の範囲第 23項にしたがうワクチン組成物。 29. 請求の範囲第14項にしたがう複合物で免疫した哺乳類で作られた抗体 からなる免疫血清。 30. 複合物の多糖類がGBS II型多糖の断片である、請求の範囲第29項にし たがう免疫血清。 31. 複合物の多糖類がGBS III型多糖の断片である、請求の範囲第29項に したがう免疫血清。 32. 請求の範囲第23項にしたがって、哺乳類に免疫に化する量のワクチン を投与することからなる、哺乳類をGBS II型またはGBS III型感染に対して免疫 する方法。 33. 哺乳類が妊娠中の女性または新生児である、請求の範囲第32項にした がう方法。 34. 請求の範囲第1項にしたがって調製した多糖断片を固形支持体に固定化 し、該固形支持体を、GBS II型抗体またはGBS III型抗体が多糖断片に結合でき る様な条件下で血清に結合した多糖と組み合わせ、また残った血清を固形支持体 から分離することからなる、GBS II型抗体またはGBS III型抗体を血清から分離 する方法。 35. 多糖断片がGBS II型である、請求の範囲第34項にしたがう方法。 36. 多糖断片がGBS III型である、請求の範囲第34項にしたがう方法。 37. 多糖断片が固形支持体に固定化される、請求の範囲第1項の方法にした がって調製された、GBS II型多糖断片またはGBS III型多糖断片からなる、免疫 アッセイ試薬。 38. 多糖断片がGBS II型である、請求の範囲第37項にしたがう免疫アッセ イ試薬。 39. 多糖断片がGBS III型である、請求の範囲第37項にしたがう免疫アッ セイ試薬。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/481,883 US6284884B1 (en) | 1995-06-07 | 1995-06-07 | Antigenic group B streptococcus type II and type III polysaccharide fragments having a 2,5-anhydro-D-mannose terminal structure and conjugate vaccine thereof |
US08/481,883 | 1995-06-07 | ||
PCT/US1996/009294 WO1996040795A1 (en) | 1995-06-07 | 1996-06-06 | Antigenic group b streptococcus type ii and type iii polysaccharide fragments having a 2, 5-anhydro-d-mannose terminal structure and conjugate vaccine thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
JPH11507964A true JPH11507964A (ja) | 1999-07-13 |
JP4001625B2 JP4001625B2 (ja) | 2007-10-31 |
Family
ID=23913768
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP50164897A Expired - Fee Related JP4001625B2 (ja) | 1995-06-07 | 1996-06-06 | 2,5−アンヒドロ−d−マンノース末端構造を持つ、抗原性グループb連鎖球菌2型および3型多糖断片とその複合ワクチン |
Country Status (15)
Country | Link |
---|---|
US (3) | US6284884B1 (ja) |
EP (1) | EP0830380B1 (ja) |
JP (1) | JP4001625B2 (ja) |
KR (1) | KR100431236B1 (ja) |
AT (1) | ATE236194T1 (ja) |
AU (1) | AU706479B2 (ja) |
CA (1) | CA2223080C (ja) |
DE (1) | DE69627149T2 (ja) |
ES (1) | ES2200067T3 (ja) |
HU (1) | HUP9900919A3 (ja) |
IL (3) | IL118603A (ja) |
NO (1) | NO975546L (ja) |
PL (1) | PL187822B1 (ja) |
WO (1) | WO1996040795A1 (ja) |
ZA (1) | ZA964822B (ja) |
Families Citing this family (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2420247A1 (en) * | 2000-08-22 | 2002-02-28 | National Research Council Of Canada | Synthesis of complex carbohydrates |
CA2881568C (en) | 2000-10-27 | 2019-09-24 | Novartis Vaccines And Diagnostics, Inc. | Nucleic acids and proteins from streptococcus groups a & b |
AU2003257003A1 (en) * | 2002-07-30 | 2004-02-16 | Baxter Healthcare S.A. | Chimeric multivalent polysaccharide conjugate vaccines |
WO2004018646A2 (en) * | 2002-08-26 | 2004-03-04 | Chiron Corporation | Conserved and specific streptococcal genomes |
PT1551357E (pt) * | 2002-09-13 | 2014-10-10 | Novartis Vaccines & Diagnostic | Vacina contra os estreptococos do grupo b |
JP4764820B2 (ja) * | 2003-06-23 | 2011-09-07 | バクスター・インターナショナル・インコーポレイテッド | ワクチン用担体タンパク質 |
ES2505695T3 (es) * | 2003-07-31 | 2014-10-10 | Novartis Vaccines And Diagnostics, Inc. | Composiciones inmunógenas para Streptococcus pyogenes |
US8945589B2 (en) * | 2003-09-15 | 2015-02-03 | Novartis Vaccines And Diagnostics, Srl | Immunogenic compositions for Streptococcus agalactiae |
WO2006078318A2 (en) * | 2004-07-29 | 2006-07-27 | Novartis Vaccines And Diagnostics Inc. | Immunogenic compositions for gram positive bacteria such as streptococcus agalactiae |
WO2006042027A2 (en) * | 2004-10-08 | 2006-04-20 | Novartis Vaccines And Diagnostics Inc. | Immunogenic and therapeutic compositions for streptococcus pyogenes |
GB0502095D0 (en) | 2005-02-01 | 2005-03-09 | Chiron Srl | Conjugation of streptococcal capsular saccharides |
WO2007023386A2 (en) * | 2005-08-24 | 2007-03-01 | Novartis Vaccines And Diagnostics Srl | Zwitterionization of capsular saccharides |
US20100015168A1 (en) * | 2006-06-09 | 2010-01-21 | Novartis Ag | Immunogenic compositions for streptococcus agalactiae |
WO2008108830A2 (en) * | 2006-10-30 | 2008-09-12 | Novartis Ag | Immunogenic and therapeutic compositions for streptococcus pyogenes |
ES2528648T3 (es) * | 2007-09-11 | 2015-02-11 | University Of Guelph | Inmunógenos polisacáridos de la Clostridium Difficile |
BRPI0816689B1 (pt) | 2007-09-12 | 2021-08-24 | Novartis Ag | Composição de vacina, kit e método para a confecção de uma composição de vacina para a prevenção ou tratamento de infecção por streptococcus pyogenes |
NZ601543A (en) | 2007-12-21 | 2013-03-28 | Novartis Ag | Mutant forms of streptolysin o |
US9358302B2 (en) | 2009-03-23 | 2016-06-07 | The Brigham And Women's Hospital, Inc. | Glycoconjugate vaccines |
GB201003333D0 (en) | 2010-02-26 | 2010-04-14 | Novartis Ag | Immunogenic proteins and compositions |
GB201005625D0 (en) | 2010-04-01 | 2010-05-19 | Novartis Ag | Immunogenic proteins and compositions |
GB201101665D0 (en) | 2011-01-31 | 2011-03-16 | Novartis Ag | Immunogenic compositions |
CN103764171B (zh) | 2011-07-08 | 2016-08-17 | 诺华股份有限公司 | 酪氨酸连接方法 |
GB201114923D0 (en) | 2011-08-30 | 2011-10-12 | Novartis Ag | Immunogenic proteins and compositions |
JP6170932B2 (ja) | 2011-11-07 | 2017-07-26 | ノバルティス アーゲー | spr0096抗原およびspr2021抗原を含むキャリア分子 |
GB201121301D0 (en) | 2011-12-12 | 2012-01-25 | Novartis Ag | Method |
RU2015106791A (ru) | 2012-10-03 | 2016-11-20 | Глэксосмитиклайн Байолоджикалз Са | Иммуногенные композиции |
EP2968427B1 (en) | 2013-03-12 | 2022-10-26 | Wellstat Vaccines, Llc | Conjugate for inducing antibodies targeting fungal cell wall polysaccharides |
KR20160040556A (ko) | 2013-07-11 | 2016-04-14 | 노파르티스 아게 | 미생물 트랜스글루타미나제를 사용한 리신-특이적 화학효소적 단백질 변형 |
US11612664B2 (en) | 2016-04-05 | 2023-03-28 | Gsk Vaccines S.R.L. | Immunogenic compositions |
BR112022023261A2 (pt) | 2020-06-12 | 2022-12-27 | Glaxosmithkline Biologicals Sa | Imunização bacteriana usando vacina de nanopartícula |
WO2023111826A1 (en) | 2021-12-14 | 2023-06-22 | Glaxosmithkline Biologicals Sa | Bacterial immunization using qbeta hairpin nanoparticle constructs |
Family Cites Families (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3352773A (en) | 1964-09-16 | 1967-11-14 | Gillette Res Inst Inc | Method of degrading polysaccharides using light radiation and a watersoluble metal or nitrogen base salt of nitrous or hyponitric acid |
US3922260A (en) | 1973-08-24 | 1975-11-25 | Quintin P Peniston | Process for depolymerization of chitosan |
US4207414A (en) | 1978-08-16 | 1980-06-10 | President And Fellows Of Harvard College | Polysaccharide antigens |
US4324887A (en) * | 1978-08-16 | 1982-04-13 | President And Fellows Of Harvard College | Type II group B Streptococci polysaccharide |
US4500519A (en) * | 1978-11-06 | 1985-02-19 | Choay S.A. | Mucopolysaccharides having biological properties, preparation and method of use |
US4439422A (en) | 1980-01-02 | 1984-03-27 | Research Corporation | Group B Streptococcus antigens and vaccines |
US4413057A (en) | 1980-04-14 | 1983-11-01 | Merck & Co., Inc. | Group B streptococcal capsular polysaccharides |
IE51174B1 (en) | 1980-04-14 | 1986-10-29 | Merck & Co Inc | Group b streptococcal capsular polysaccharides |
US4438261A (en) | 1980-05-19 | 1984-03-20 | Riker Laboratories, Inc. | Anticoagulant substance |
US4367223A (en) | 1980-06-09 | 1983-01-04 | President And Fellows Of Harvard College | Vaccine against Group B streptococci |
US4367221A (en) | 1980-06-09 | 1983-01-04 | President And Fellows Of Harvard College | Immunization against Group B streptococci |
US4356263A (en) | 1980-06-09 | 1982-10-26 | President And Fellows Of Harvard College | Method of making a polysaccharide vaccine |
US4367222A (en) | 1980-06-09 | 1983-01-04 | President And Fellows Of Harvard College | Immune globulin specific to Group B streptococci |
US4284537A (en) | 1980-07-03 | 1981-08-18 | The United States Of America As Represented By The Department Of Health And Human Services | Conjugate of streptococcal M protein peptide vaccine |
US4425330A (en) | 1981-05-20 | 1984-01-10 | Cornell Research Foundation, Inc. | Bovine mastitis vaccine and method for detecting efficacy thereof |
US4356170A (en) * | 1981-05-27 | 1982-10-26 | Canadian Patents & Development Ltd. | Immunogenic polysaccharide-protein conjugates |
US4902506A (en) | 1983-07-05 | 1990-02-20 | The University Of Rochester | Immunogenic conjugates |
US4619828A (en) | 1982-07-06 | 1986-10-28 | Connaught Laboratories, Inc. | Polysaccharide exotoxoid conjugate vaccines |
US4757134A (en) | 1982-12-02 | 1988-07-12 | The Rockefeller University | IgA binding protein |
DE3584866D1 (de) | 1984-09-12 | 1992-01-23 | Chiron Corp | Hybridpartikel-immunogene. |
FR2581877B1 (fr) | 1985-05-14 | 1987-12-18 | Louvain Universite Catholique | Conjugue constitue d'une adhesine de paroi de s. mutans, de nature proteique et d'un polysaccharide de s. mutans, sa preparation et son utilisation notamment dans des vaccins anti-caries |
IT1187753B (it) | 1985-07-05 | 1987-12-23 | Sclavo Spa | Coniugati glicoproteici ad attivita' immunogenica trivalente |
WO1987006267A1 (en) | 1986-04-16 | 1987-10-22 | The Brigham And Women's Hospital, Inc. | Bacterial antigens, antibodies, vaccines, and methods of manufacture |
US5302386A (en) | 1986-04-16 | 1994-04-12 | Brigham And Women's Hospital, Inc. | Bacterial antigens, antibodies, vaccines and methods of manufacture |
EP0419462A4 (en) | 1987-07-17 | 1991-07-17 | Xoma Corporation | Improved immunotoxin therapies utilizing purified ricin a-chain species |
JP2871822B2 (ja) | 1989-08-29 | 1999-03-17 | 玉造株式会社 | 末端に2,5―アンヒドロマンニトール基または2,5―アンヒドロマンノース基を有するキチン・キトサンオリゴマーおよびその製造方法 |
IL95578A (en) | 1989-09-15 | 1998-08-16 | Gen Hospital Corp | A vaccine made from polysaccharide and protein |
AU6538490A (en) | 1989-09-18 | 1991-04-18 | Brigham And Women's Hospital | Enzymatic generation and recovery of group b streptococcus type iii capsular oligosaccharides |
KR0158436B1 (ko) | 1989-12-14 | 1998-12-01 | 피에르 오. 페론 | 개선된 수막염균성 폴리사카라이드 결합체 백신 |
US5153312A (en) | 1990-09-28 | 1992-10-06 | American Cyanamid Company | Oligosaccharide conjugate vaccines |
JPH06506114A (ja) | 1991-03-29 | 1994-07-14 | ファウルマン, エルビン | 新規な遺伝子及びIgA結合蛋白質の製造方法 |
FR2682388B1 (fr) | 1991-10-10 | 1995-06-09 | Pasteur Merieux Serums Vacc | Procede de preparation d'un oligoside par depolymerisation d'un polyoside issu d'un agent pathogene, oligoside ainsi obtenu et son utilisation notamment comme agent vaccinal. |
US5352588A (en) | 1991-12-24 | 1994-10-04 | Rockefeller University | Streptococcal immunoglobulin a binding protein encoded by emmL2.2 |
JPH07503543A (ja) * | 1992-02-04 | 1995-04-13 | クイデル コーポレイション | 乾燥試薬を用いる細菌抗原の簡易化抽出法 |
ZA937034B (en) | 1992-09-24 | 1995-06-23 | Brigham & Womens Hospital | Group B streptococcus type II and type V polysaccharide-protein conjugate vaccines |
IL107458A0 (en) | 1992-11-02 | 1994-02-27 | Gen Hospital Corp | Conjugate vaccine against group b streptococcus |
US5439808A (en) * | 1993-07-23 | 1995-08-08 | North American Vaccine, Inc. | Method for the high level expression, purification and refolding of the outer membrane group B porin proteins from Neisseria meningitidis |
US5595740A (en) * | 1994-05-16 | 1997-01-21 | University Of Florida | Cloning of non-IgA FC binding forms of the group B streptococcal beta antigens |
KR100413907B1 (ko) | 1998-12-22 | 2004-01-07 | 미쓰비시덴키 가부시키가이샤 | 전지용 전해액 및 이를 사용한 전지 |
-
1995
- 1995-06-07 US US08/481,883 patent/US6284884B1/en not_active Expired - Fee Related
-
1996
- 1996-06-06 KR KR1019970709189A patent/KR100431236B1/ko not_active IP Right Cessation
- 1996-06-06 AU AU60953/96A patent/AU706479B2/en not_active Ceased
- 1996-06-06 EP EP96918253A patent/EP0830380B1/en not_active Expired - Lifetime
- 1996-06-06 DE DE69627149T patent/DE69627149T2/de not_active Expired - Fee Related
- 1996-06-06 PL PL96323822A patent/PL187822B1/pl not_active IP Right Cessation
- 1996-06-06 CA CA002223080A patent/CA2223080C/en not_active Expired - Fee Related
- 1996-06-06 JP JP50164897A patent/JP4001625B2/ja not_active Expired - Fee Related
- 1996-06-06 ES ES96918253T patent/ES2200067T3/es not_active Expired - Lifetime
- 1996-06-06 HU HU9900919A patent/HUP9900919A3/hu unknown
- 1996-06-06 WO PCT/US1996/009294 patent/WO1996040795A1/en active IP Right Grant
- 1996-06-06 AT AT96918253T patent/ATE236194T1/de not_active IP Right Cessation
- 1996-06-07 IL IL11860396A patent/IL118603A/xx not_active IP Right Cessation
- 1996-06-07 ZA ZA964822A patent/ZA964822B/xx unknown
- 1996-06-07 IL IL136125A patent/IL136125A/en not_active IP Right Cessation
-
1997
- 1997-12-02 NO NO975546A patent/NO975546L/no unknown
-
1998
- 1998-02-18 US US09/025,225 patent/US6372222B1/en not_active Expired - Fee Related
-
2000
- 2000-05-14 IL IL13612500A patent/IL136125A0/xx active IP Right Grant
-
2001
- 2001-05-18 US US09/861,131 patent/US6602508B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
DE69627149D1 (de) | 2003-05-08 |
NO975546L (no) | 1998-02-06 |
ZA964822B (en) | 1997-01-07 |
IL118603A (en) | 2000-12-06 |
ATE236194T1 (de) | 2003-04-15 |
US6372222B1 (en) | 2002-04-16 |
EP0830380B1 (en) | 2003-04-02 |
HUP9900919A2 (hu) | 1999-06-28 |
US6284884B1 (en) | 2001-09-04 |
PL323822A1 (en) | 1998-04-27 |
KR100431236B1 (ko) | 2004-09-16 |
DE69627149T2 (de) | 2003-12-04 |
AU706479B2 (en) | 1999-06-17 |
EP0830380A1 (en) | 1998-03-25 |
WO1996040795A1 (en) | 1996-12-19 |
NO975546D0 (no) | 1997-12-02 |
US20020031526A1 (en) | 2002-03-14 |
US6602508B2 (en) | 2003-08-05 |
IL136125A0 (en) | 2001-05-20 |
JP4001625B2 (ja) | 2007-10-31 |
IL118603A0 (en) | 1996-10-16 |
KR19990022747A (ko) | 1999-03-25 |
CA2223080A1 (en) | 1996-12-19 |
IL136125A (en) | 2006-08-01 |
AU6095396A (en) | 1996-12-30 |
ES2200067T3 (es) | 2004-03-01 |
HUP9900919A3 (en) | 2000-04-28 |
CA2223080C (en) | 2007-03-20 |
PL187822B1 (pl) | 2004-10-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4001625B2 (ja) | 2,5−アンヒドロ−d−マンノース末端構造を持つ、抗原性グループb連鎖球菌2型および3型多糖断片とその複合ワクチン | |
JP4097691B2 (ja) | C群髄膜炎菌に対するワクチン | |
AU2005316864B2 (en) | Glycoconjugate vaccines containing peptidoglycan | |
JP2736248B2 (ja) | 莢膜ポリマーフラグメントの製造方法 | |
Paoletti et al. | Effects of chain length on the immunogenicity in rabbits of group B Streptococcus type III oligosaccharide-tetanus toxoid conjugates. | |
NO300759B1 (no) | Fremgangsmåte for fremstilling av et kovalent konjugat av et oligosakkarid og et bærerprotein | |
JP2009227680A (ja) | 腸球菌抗原およびワクチン | |
JPH09512276A (ja) | A群ストレプトコッカス細菌ポリサッカライドの免疫原性組成物及び免疫法 | |
SK15122003A3 (sk) | Imunogénne konjugáty nízkomolekulárnej kyseliny hyalurónovej s polypeptidovými toxínmi | |
US9616139B2 (en) | Conjugating amines | |
Liao et al. | Characterization of a human monoclonal immunoglobulin M (IgM) antibody (IgMBEN) specific for Vi capsular polysaccharide of Salmonella typhi | |
AU2002342321A1 (en) | Immunogenic conjugates of low molecular weight hyaluronic acid with polypeptide toxins |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20061114 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20070213 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20070402 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20070514 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20070717 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20070815 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100824 Year of fee payment: 3 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
LAPS | Cancellation because of no payment of annual fees |